If Medicare will not pay, these two programs take cash, no insurance needed.
- SnagRx$99 a monthcompounded semaglutideCheck price →SnagRx's homepage shows its 12-month prepaid prices first
- yourEra$89 a monthcompounded semaglutideCheck price →
Cheapest GLP-1 without insurance compares the three cash routes. Cheapest GLP-1 ranks every cash price on the chart.
Coverage at a glance
| Indication | Coverage |
|---|---|
| Wegovy for cardiovascular risk reduction (SELECT indication) | Covered with prior authorization |
| Zepbound for obstructive sleep apnea (SURMOUNT-OSA indication) | Covered with prior authorization |
| Type 2 diabetes | Covered with prior authorization |
Prior authorization: the plan reviews the prescription before it pays.
No for weight loss alone. The 2003 Medicare Part D law bars it. Wellcare does cover Wegovy to lower cardiovascular risk, and Zepbound for sleep apnea. It covers the diabetes brands for type 2 diabetes. In each case the drug has to be on your own plan's drug list. This answer covers Medicare Advantage Part D and Medicare Part D.
Source: Wellcare, Does Medicare Cover Weight-Loss Drugs? Understanding GLP-1 Coverage in 2026. Checked June 12, 2026.
What your plan charges. The Wellcare Classic (PDP) 2026 drug list puts Ozempic and Mounjaro on tier 3, its preferred brand tier, both with prior authorization and a quantity limit. The plan's 2026 annual notice of change sets standard tier 3 cost sharing at 25 percent of the total cost. Wegovy and Zepbound are not on that formulary. Sources: Wellcare Classic (PDP) 2026 Formulary, updated September 1, 2026. Wellcare Classic (PDP) Annual Notice of Change for 2026. Checked September 6, 2026.
Coverage by indication
| BMI threshold | BMI 27 or higher |
| Cardiovascular criteria | Established cardiovascular disease, judged by the criteria used in the SELECT trial |
What the prior authorization needs:
- Wegovy must appear on the specific plan's drug list
- The plan signs off, with a written record of established cardiovascular disease
- Not covered for weight loss alone, because the Medicare law rules it out
Source: Wellcare, Does Medicare Cover Weight-Loss Drugs? Understanding GLP-1 Coverage in 2026. Wellcare's own member page, read as HTML.
| BMI threshold | BMI 30 or higher |
| Sleep study (AHI) | Moderate to severe obstructive sleep apnea, at an AHI of 15 or higher, per the SURMOUNT-OSA criteria |
What the prior authorization needs:
- Zepbound must appear on the specific plan's drug list
- The plan signs off, with a written record of the obstructive sleep apnea diagnosis
- Not covered for weight loss alone, because the Medicare law rules it out
Source: Wellcare, Does Medicare Cover Weight-Loss Drugs? Understanding GLP-1 Coverage in 2026. Wellcare's own member page, read as HTML.
This is the standard Medicare Part D coverage for GLP-1s used in type 2 diabetes. It runs for Ozempic, Mounjaro and Trulicity. The Part D obesity exclusion does not apply to it.
What the prior authorization needs:
- Type 2 diabetes diagnosis
- The drug must appear on the plan's formulary
- The plan signs off, with the A1c and a written record of the diabetes
Source: Wellcare, Does Medicare Cover Weight-Loss Drugs? Understanding GLP-1 Coverage in 2026. Wellcare's own member page, read as HTML.
Formulary note: The drug has to be on your own plan's drug list before it is covered. The Medicare GLP-1 Bridge, which started in July 2026, adds a $50 a month route for Part D members who qualify.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Start with the Wellcare Medicare prior-authorization letter template, which cites this plan's policy and the diagnosis codes a reviewer looks for. Pick the indication that matches your clinical picture.
- Read why plans say no and the four ways to appeal in the GLP-1 insurance guide.
- If the plan denies it, the appeal letter library has a template for each reason a plan gives. That covers the peer-to-peer call with a plan doctor, the Level 1 and Level 2 appeals inside the plan, and the outside review that follows them.
- If your plan does not cover the indication you need, compare the cheapest GLP-1 cash prices or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time.
What it costs without insurance
The programs below bill you directly. Prices checked every Monday.
Frequently asked questions
Does Wellcare cover Zepbound for weight loss or sleep apnea?
Not for weight loss alone, because the 2003 Medicare Part D law bars it. For obstructive sleep apnea, yes with plan approval: a BMI of 30 or higher, moderate to severe sleep apnea (an AHI of 15 or more breathing stops an hour), and Zepbound on your own plan's drug list. The 2026 Wellcare Classic (PDP) drug list does not carry it. Policy checked June 2026.
Does Wellcare cover Wegovy for weight loss?
No. The 2003 Medicare Part D law bars coverage for weight loss alone. Wellcare covers Wegovy to lower cardiovascular risk, with plan approval, for people with established cardiovascular disease and a BMI of 27 or higher, when Wegovy is on their own plan's drug list. The 2026 Wellcare Classic (PDP) drug list does not carry it. Policy checked June 2026.
Does Wellcare cover Ozempic or Mounjaro?
For type 2 diabetes, yes with plan approval if it is on your own plan's drug list. The 2026 Wellcare Classic (PDP) drug list puts both on tier 3, its preferred brand tier, with prior authorization and a quantity limit. The Part D weight-loss exclusion does not apply to diabetes use.
Can a Wellcare member get Wegovy or Zepbound for weight loss at all?
Through the Medicare GLP-1 Bridge, if you qualify. It is Medicare's own program for people on a standalone Part D plan or most Medicare Advantage plans with drug coverage. You need a BMI of 35 or higher on its own, or 30 or 27 with a listed condition, and your doctor sends the prior authorization request to Medicare, not Wellcare. It covers Foundayo, Wegovy and the Zepbound KwikPen, and it ends on December 31, 2027.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Every page here comes from the payer's own policy, a federal law, or KFF's plan research. Each row links its source and gives the date we read it. Some plan files load at the address the payer gives but will not open. We check those against a second source and mark the row lower confidence. Job-based plans also choose whether to add the weight-drug benefit at all, so those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.